Independent Lab Analysis Reveals Contaminants and Dosage Issues in Peptide Samples

Peptides such as BPC-157, TB-500, and CJC-1295 are substances promoted for uses including injury recovery, inflammation reduction, and growth hormone stimulation. U.S. Food and Drug Administration. Users include athletes, biohackers, and individuals seeking anti-aging benefits, though clinical evidence remains limited.

An independent laboratory conducted testing on samples of these peptides, as reported by Eric Topol. The analysis focused on purity, contaminants, and dosage accuracy. Results indicated potential health risks associated with the products' composition.

The vial of BPC-157 tested positive for lead contamination.

Lead is a heavy metal that can cause neurological and other health issues with prolonged exposure. This finding raises questions about manufacturing standards for such supplements. The TB-500 sample contained endotoxins, which are bacterial byproducts that can trigger immune responses and inflammation.

Endotoxins in injectable products may lead to adverse reactions in users. The presence of these substances suggests possible lapses in production hygiene. The CJC-1295 vial had less than 42% of the advertised dose.

This under-dosing could affect the intended physiological effects, if any, and highlights variability in product potency. Consumers relying on labeled dosages may not receive the expected amounts.

like these lack comprehensive data on long-term safety and efficacy, according to reports from experts including Eric Topol.

There is also no assurance of sterility in many available products, increasing risks of infection. Regulatory bodies have issued warnings about unapproved peptides, but enforcement varies. Affected parties include consumers purchasing these peptides for personal use, as well as clinics offering them in treatments.